NLS Pharmaceutics Ltd. Warrant (NLSPW)

NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

NLS Pharmaceutics and Kadimastem have been granted a Hong Kong patent for cell-selection technology used in IsletRx, a stem cell-derived therapy for insulin-dependent diabetes, expanding their intellectual property protection in Asia.